MEK1 (Phospho-Ser217) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-MEK1 (Phospho-Ser217) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | MEK1 (Phospho-Ser217) |
| Clone | polyclonal |
| Host Species | n/a |
| Reactive Species | human, mouse, rat |
| Isotype | n/a |
| Format | epitope affinity purified |
| Size | 0.05 mg, 0.1 mg |
| Concentration | n/a |
| Applications | Immunohistochemistry (IHC) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: MEK1 (phospho-Ser217) antibody detects endogenous levels of MEK1 only when phosphorylated at serine 217. |
| Immunogen | Immunogen: The antiserum was produced against synthesized phosphopeptide derived from human MEK1 around the phosphorylation site of serine 217 (I-D-SP-M-A). |
| Other Names | [dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 1; dual specificity mitogen-activated protein kinase kinase 1; mitogen-activated protein kinase kinase 1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1], [MAP2K1; MAP2K1; CFC3; MEK1; MKK1; MAPKK1; PRKMK1; MEK1; PRKMK1; MAP kinase kinase 1; MAPKK 1; MKK1; MEK 1] |
| Gene, Accession # | [MEK1], Gene ID: 5604, NCBI: NP_002746.1, UniProt: Q02750 |
| Catalog # | MBS856847 |
| Price | $215, $280 |
| Order / More Info | MEK1 (Phospho-Ser217) Antibody from MYBIOSOURCE INC. |
| Product Specific References | Shen R, et al. (2002) Mol Cell Biol; 22(10): 3230-3236 Preisinger C, et al. (2005) EMBO J; 24(4): 753-765 Laine P, et al. (2000) Biochem J; 349(Pt 1): 19-25 Yaglom J, et al. (2003) Mol Cell Biol; 23(11): 3813-3824 Dahan S, et al. (2002) Infect Immun; 70(5): 2304-2310. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies